​

Structure Therapeutics (GPCR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

GPCR Stock Forecast

Structure Therapeutics (GPCR) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $92.40, with a high of $118.00 and a low of $65.00. This represents a 219.17% increase from the last price of $28.95.

$25 $44 $63 $82 $101 $120 High: $118 Avg: $92.4 Low: $65 Last Closed Price: $28.95

GPCR Stock Rating

Structure Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

GPCR Price Target Upside V Benchmarks

TypeNameUpside
StockStructure Therapeutics219.17%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$28.95$28.95$28.95
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2559---14
Sep, 2558---13
Aug, 2567---13
Jul, 2568---14
Jun, 2568---14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 23, 2024Terence FlynnMorgan Stanley$118.00$41.92181.49%307.60%
Sep 10, 2024Yasmeen RahimiPiper Sandler$93.00$34.72167.86%221.24%
Aug 09, 2024Jonathan WollebenJMP Securities$86.00$34.49149.35%197.06%
Jun 07, 2024Evan SeigermanBMO Capital$100.00$53.0788.43%245.42%
Apr 09, 2024Prakhar AgrawalCantor Fitzgerald$65.00$44.4146.36%124.53%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2025Piper SandlerOverweightOverweighthold
Aug 07, 2025H.C. WainwrightBuyBuyhold
Feb 27, 2025William BlairOutperforminitialise
Oct 21, 2024BMO CapitalOutperformOutperformhold
Sep 23, 2024Morgan StanleyOverweightinitialise
Sep 10, 2024Piper SandlerOverweightOverweighthold
Aug 09, 2024JMP SecuritiesOutperformOutperformhold
Jun 07, 2024BMO CapitalOutperformOutperformhold
Apr 09, 2024Cantor FitzgeraldOverweightinitialise
Oct 03, 2023BMO CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.20$-0.78----
Avg Forecast$-0.83$-0.80$-0.81$-1.52$-1.97$-2.05
High Forecast$-0.78$-0.73$2.53$-1.05$-1.08$-2.05
Low Forecast$-0.87$-1.00$-2.05$-2.18$-3.15$-2.05
Surprise %-75.90%-2.50%----

Revenue Forecast

$145M $156M $167M $178M $189M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$45.45M-$148.80M$199.50M
High Forecast--$45.45M-$148.80M$199.50M
Low Forecast--$45.45M-$148.80M$199.50M
Surprise %------

Net Income Forecast

$-2B $-900M $-300M $300M $900M $2B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-89.62M$-122.53M----
Avg Forecast$-363.78M$-380.80M$-119.43M$-712.07M$-933.34M$-902.74M
High Forecast$-345.07M$-322.71M$1.11B$-461.62M$-477.92M$-902.74M
Low Forecast$-382.49M$-438.89M$-901.73M$-962.52M$-1.39B$-902.74M
Surprise %-75.36%-67.82%----

GPCR Forecast FAQ

Is Structure Therapeutics stock a buy?

Structure Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Structure Therapeutics is a favorable investment for most analysts.

What is Structure Therapeutics's price target?

Structure Therapeutics's price target, set by 8 Wall Street analysts, averages $92.4 over the next 12 months. The price target range spans from $65 at the low end to $118 at the high end, suggesting a potential 219.17% change from the previous closing price of $28.95.

How does Structure Therapeutics stock forecast compare to its benchmarks?

Structure Therapeutics's stock forecast shows a 219.17% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Structure Therapeutics over the past three months?

  • October 2025: 35.71% Strong Buy, 64.29% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 38.46% Strong Buy, 61.54% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 46.15% Strong Buy, 53.85% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Structure Therapeutics’s EPS forecast?

Structure Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.81, marking a 3.85% increase from the reported $-0.78 in 2024. Estimates for the following years are $-1.52 in 2026, $-1.97 in 2027, and $-2.05 in 2028.

What is Structure Therapeutics’s revenue forecast?

Structure Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $45.45M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $148.8M for 2027, and $199.5M for 2028.

What is Structure Therapeutics’s net income forecast?

Structure Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-119M, representing a -2.52% decrease from the reported $-123M in 2024. Projections indicate $-712M in 2026, $-933M in 2027, and $-903M in 2028.